Goodwin advised TCR2 Therapeutics on the completion of its highly oversubscribed $125 million Series B financing round.
Proceeds of the financing will be used to advance two TRuC™-T cell programs through human proof-of-concept, including its lead solid tumor program TC-210 targeting mesothelin. Proceeds will also support further expansion of the company’s multi-format TRuC™ platform with a pipeline that includes dual-target TRuC™, immune cell enhancements and allogeneic technologies.
The financing was co-led by 6 Dimensions Capital and Curative Ventures with participation from new investors including Redmile Group, ArrowMark Partners, Hillhouse Capital Group, MiraeAsset Financial Group, Syno Capital, Haitong International Securities, Lucion Group, Sirona Capital, Alexandria Venture Investments and entities affiliated with Leerink Partners. They were joined by all of the company’s existing investors – MPM Capital (MPM BioVentures 2014 and UBS Oncology Impact Fund by MPM Capital), F2 Ventures and Cathay Fortune Capital Investment.
TCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors and blood cancers that utilize the full signaling power of complete T cell receptors (TCR) without the need for HLA-matching. The company, led by Garry Menzel, Robert Hofmeister, Alfonso Quintás Cardama, Andrew Cornforth, Daniel Getts, Helen Ho, Amy Lynch, Gregory Sieczkiewicz and Stephen Turkowiak, is based in Cambridge (MA).
The Goodwin team was led by partners Bill Collins (Picture) and Mitchell Bloom and included associates Daniel Issacs, Tyler Vandeventer and Amani Kancey.
Law Firms: Goodwin Procter;
Clients: TCR2 Therapeutics;